Lancet Regional Health-Americas最新文献

{"title":"Addressing migrant-specific barriers to accessing health services through primary health care in host countries in Latin American and the Caribbean","authors":"James Fitzgerald,&nbsp;Ernesto Báscolo,&nbsp;Gustavo Rosell de Almeida,&nbsp;Natalia Houghton,&nbsp;Rachel Jarboe,&nbsp;Julie Issa","doi":"10.1016/j.lana.2024.100957","DOIUrl":"10.1016/j.lana.2024.100957","url":null,"abstract":"<div><div>The Region of Latin America and the Caribbean (LAC) is a culturally rich region marked by significant bio- and sociocultural diversity, including approximately 50 million Indigenous People. However, LAC faces deep inequalities and vast disparities between social development and economic progress, including in access to healthcare for migrant populations. Migration has historically always existed in the region with current movements characterized by a south-south pattern within LAC combined with a south-north pattern from LAC, moving towards North America. Furthermore, environmental degradation and climate change have increasingly contributed to a substantial rise in migration as well as health risks for migrants in the Region, and it is predicted to accelerate in coming years.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100957"},"PeriodicalIF":7.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zulma M. Cucunubá — shaping public health with mathematical modelling","authors":"Taissa Vila","doi":"10.1016/j.lana.2024.100958","DOIUrl":"10.1016/j.lana.2024.100958","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100958"},"PeriodicalIF":7.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study","authors":"Phyumar Soe ,&nbsp;Otto G. Vanderkooi ,&nbsp;Manish Sadarangani ,&nbsp;Monika Naus ,&nbsp;Matthew P. Muller ,&nbsp;James D. Kellner ,&nbsp;Karina A. Top ,&nbsp;Hubert Wong ,&nbsp;Jennifer E. Isenor ,&nbsp;Kimberly Marty ,&nbsp;Hennady P. Shulha ,&nbsp;Gaston De Serres ,&nbsp;Louis Valiquette ,&nbsp;Allison McGeer ,&nbsp;Julie A. Bettinger","doi":"10.1016/j.lana.2024.100949","DOIUrl":"10.1016/j.lana.2024.100949","url":null,"abstract":"<div><h3>Background</h3><div>The Canadian National Vaccine Safety Network conducted active safety surveillance for COVID-19 vaccines. This study aimed to characterize the short-to-medium term safety of mRNA COVID-19 vaccines across the pediatric age spectrum.</div></div><div><h3>Methods</h3><div>In this cohort study, vaccinated and unvaccinated children and adolescents aged 6 months to 19 years from eight Canadian provinces and territories were invited to participate. The outcome was a health event preventing daily activities, resulting in school absenteeism, or requiring medical consultation. Age-stratified multivariable regression models were used to examine health events associated with first and second doses of mRNA COVID-19 vaccines across different age groups: children under 5, children aged 5–11 years and adolescents aged 12–19 years.</div></div><div><h3>Findings</h3><div>From January 2021 through February 2023, a total of 259,361 individuals from the dose one survey, 131,032 from the dose 2 survey, and 1179 from the control survey were included. In the week following dose two, vaccinated adolescents showed a higher proportion of health events [794 (4.6%) of 17,218 BNT162b2 recipients, 98 (8.5%) of 1153 mRNA-1273 recipients, 49 of (10.6%) of 464 heterologous schedule recipients] than unvaccinated adolescents [9 (3.7%) of 242 controls], but most events were self-limited and resolved within 7 days. No significant differences in proportion of health events following mRNA COVID-19 vaccines were observed between vaccinated and unvaccinated groups among adolescents after dose 1, or among children under 5 or those aged 5–11 years after any dose. Reported myocarditis/pericarditis cases within 0–28 days peaked among male adolescents following dose 2, in three of (0.037%) 8088 homologous BNT162b2 recipients, and two of (0.529%) 378 homologous mRNA-1273 recipients.</div></div><div><h3>Interpretation</h3><div>Our findings suggest that reported health events, including myocarditis/pericarditis, vary by pediatric age group. Vaccinated adolescents reported health events more frequently following the second mRNA COVID-19 vaccine dose, while younger age groups did not report events more frequently than their unvaccinated counterparts.</div></div><div><h3>Funding</h3><div><span>Canadian Immunization Research Network</span>, <span>Canadian Institutes of Health Research</span>; <span>Public Health Agency of Canada</span>; <span>COVID-19 Immunity Task Force</span>.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100949"},"PeriodicalIF":7.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain and brain blood vessels histological description in autopsies of fetuses/neonates born to mothers with hypertension during pregnancy. A case–control study","authors":"Johana González ,&nbsp;Jorge Anxdrés Franco ,&nbsp;Carlos Escudero ,&nbsp;Mercedes Olaya","doi":"10.1016/j.lana.2024.100955","DOIUrl":"10.1016/j.lana.2024.100955","url":null,"abstract":"<div><h3>Background</h3><div>Children born to women with hypertension during pregnancy have a two to threefold increased risk of developing cognitive disorders compared to children born to women without hypertension. However, structural changes in the central nervous system of these children remain poorly understood. We aim to compare the brain histological findings from autopsies of neonates and fetuses born to women with and without hypertension during pregnancy.</div></div><div><h3>Methods</h3><div>This retrospective case–control study includes brain histological samples from autopsies of neonates and fetuses born to women with (n = 22) and without (n = 15) hypertension during pregnancy, obtained from biobanks associated with the University Hospital San Ignacio (HUSI), Bogotá, Colombia, between 2007 and 2022. Hypertension during pregnancy was diagnosed following American College of Obstetricians and Gynecologists (ACOG) guidelines. Matched criteria included similar maternal pre-pregnancy morbidity, gestational ages at delivery, fetal sex, and availability of similar histological samples of fetal/neonatal brains. Clinical data were recorded, and two diagnosed-blinded pathologists analyzed all slides.</div></div><div><h3>Findings</h3><div>Ninety-three percent (14/15) of fetuses/neonates born to women with hypertension during pregnancy were born after preeclamptic pregnancies. Histological findings were described for the frontotemporal cortex (97%, 36/37) and meninges (81%, 30/37). Fetuses/neonates born to women with hypertension during pregnancy were smaller (p = 0.030), had a lower gestational age at death (p = 0.047), and were more frequently stillborn. Autopsy records revealed higher maternal vascular malperfusion in women with hypertension during pregnancy (p &lt; 0.0001). Subarachnoid hemorrhage was more common in fetuses/neonates born to women with hypertension during pregnancy (p = 0.036). Other frequent findings included neuropil edema, congested meninges, hypoxic-ischemic encephalopathy, subdural hematoma, venous sinus thrombosis, hemoventricle, and necrotic foci. However, no significant endothelial or vascular wall changes were noted. “Prominent and congested” capillaries were observed only in fetuses/neonates born to women without hypertension.</div></div><div><h3>Interpretation</h3><div>The findings suggest increased cerebrovascular vulnerability in fetuses and neonates exposed to maternal hypertension during pregnancy, with a higher incidence of subarachnoid hemorrhage. While no vascular wall changes were identified, fewer brain capillary alterations were noted in those born to women with hypertension during pregnancy.</div></div><div><h3>Funding</h3><div><span>Fondecyt</span> 1200250, 1240295.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"41 ","pages":"Article 100955"},"PeriodicalIF":7.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes","authors":"Leonardo G. da Fonseca ,&nbsp;Laura Izquierdo-Sanchez ,&nbsp;Pedro H. Hashizume ,&nbsp;Yanina Carlino ,&nbsp;Estefanía Liza Baca ,&nbsp;Cristina Zambrano ,&nbsp;Santiago A. Sepúlveda ,&nbsp;Andrea Bolomo ,&nbsp;Pedro M. Rodrigues ,&nbsp;Ioana Riaño ,&nbsp;Andre Boonstra ,&nbsp;Jose D. Debes ,&nbsp;Luis Bujanda ,&nbsp;Flair J. Carrilho ,&nbsp;Marco Arrese ,&nbsp;Juan C. Roa ,&nbsp;Enrique Carrera ,&nbsp;Javier Díaz Ferrer ,&nbsp;Domingo Balderramo ,&nbsp;Claudia P. Oliveira ,&nbsp;Jesus M. Banales","doi":"10.1016/j.lana.2024.100952","DOIUrl":"10.1016/j.lana.2024.100952","url":null,"abstract":"<div><h3>Background</h3><div>Cholangiocarcinoma (CCA) represents a global health challenge, with rising incidence and mortality rates. This study aimed to elucidate the clinical course and practices of CCA in Latin America.</div></div><div><h3>Methods</h3><div>This observational cohort study investigated individuals diagnosed with CCA between 2010 and 2023 at five referral centres across Latin America. Demographic, biochemical, and clinical data were analysed.</div></div><div><h3>Findings</h3><div>A total of 309 patients were enrolled, demonstrating a balanced distribution of CCA subtypes (intrahepatic, perihilar, and distal), with Hispanics and Caucasians as the predominant ethnic groups, followed by Africans. Major risk factors identified included age, diabetes, obesity, MASLD, bile duct stones, and cholecystitis. Disparities in overweight/obesity prevalence were noted among CCA subtypes and ethnicities, with higher rates in extrahepatic CCA and among Hispanics and Caucasians. At diagnosis, 72% of patients had ECOG-PS scores of 0–1, with disease presentations ranging from localized (47%) to locally advanced (19%) and metastatic (34%). Patients who did not receive any anti-cancer therapy exhibited a median survival of 2.3 months. Survival rates significantly improved across treatment modalities, with surgery yielding the longest (34 months), followed by chemotherapy (8 months). Notably, Africans presented with worse ECOG-PS scores and more advanced disease, while Hispanics were less frequently treated with chemotherapy for advanced disease, contributing to lower survival rates (8.3 and 6 months, respectively) compared to Caucasians (12.6 months).</div></div><div><h3>Interpretation</h3><div>The high prevalence of late-stage CCA diagnosis in Latin America, particularly among individuals of African ethnicity, coupled with a significant proportion of Hispanic patients not receiving chemotherapy, underscores the dismal prognosis for these patients. These findings reveal structural challenges in cancer screening and healthcare access among diverse ethnic backgrounds and lower socioeconomic statuses in the region. Urgent measures are needed, including the identification of preventable risk factors, raising awareness among high-risk populations, and establishing equitable health coverage to address these disparities.</div></div><div><h3>Funding</h3><div><span>European Union’s Horizon 2020 R&amp;I Program</span>, <span>Incyte Bioscience International Sàrl</span>, and <span>European Association for the Study of the Liver</span> (EASL).</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100952"},"PeriodicalIF":7.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shattering the monolith: burden of gastrointestinal cancer in Asian Americans, Native Hawaiians, and Pacific Islanders in the United States","authors":"Ji Yoon Yoon ,&nbsp;Shailja C. Shah ,&nbsp;Jenny J. Lin ,&nbsp;Michelle Kang Kim ,&nbsp;Steven H. Itzkowitz ,&nbsp;Christina P. Wang","doi":"10.1016/j.lana.2024.100954","DOIUrl":"10.1016/j.lana.2024.100954","url":null,"abstract":"<div><div>Asian Americans remain the fastest-growing racial group in the United States, and are anticipated to double over the next few decades. Asian Americans are the only major racial-ethnic group for whom cancer remains the leading cause of death, and multiple gastrointestinal cancers rank among the top five incident and fatal cancers. Most research to date presents Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPI) in aggregate, overlooking their vast heterogeneity and hindering efforts to identify and address health disparities within AANHPI origin groups. Here, we present gastrointestinal cancer incidence and mortality in AANHPI, including disaggregated rates where feasible, and highlight gaps in current screening practices. We conclude with actionable suggestions to shift away from using broad racial categories to evaluate cancer disparities, towards high-quality, disaggregated data to better isolate and address factors driving the clear differential cancer risks among AANHPI.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"41 ","pages":"Article 100954"},"PeriodicalIF":7.0,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial utilisation patterns between 2013 and 2022 in Canadian neonates born at less than 33 weeks gestation: a retrospective cohort study","authors":"Joseph Y. Ting ,&nbsp;Shikha Gupta-Bhatnagar ,&nbsp;Julie Choudhury ,&nbsp;Eugene W. Yoon ,&nbsp;Guillaume Ethier ,&nbsp;Rebecca Sherlock ,&nbsp;Jennifer Toye ,&nbsp;Marc Beltempo ,&nbsp;Prakesh S. Shah ,&nbsp;Canadian Neonatal NetworkTM","doi":"10.1016/j.lana.2024.100942","DOIUrl":"10.1016/j.lana.2024.100942","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Excessive antimicrobial exposure is associated with an increase in neonatal mortality, morbidities and adverse neurodevelopment. Canadian Neonatal Network has been promoting judicious antimicrobial use through the Evidence-based Practice for Improving Quality processes. Our objective was to evaluate the antimicrobial consumption among neonates in tertiary neonatal intensive care units (NICU) in Canada in the recent decade.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This is a retrospective cohort study including data from very preterm infants (born at &lt;33 weeks gestational age) admitted to all NICUs in Canada between January 1, 2013, and December 31, 2022. Nationwide antimicrobial utilization rate (AUR) benchmarking started in 2016, and quality improvement initiatives were continued in the subsequent years to promote judicious use of antimicrobials across the network. AUR is defined as the number of days with ≥1 antimicrobial divided by the total patient days (PD). Culture-proven sepsis refers to a neonate with positive culture of pathogens in blood and/or cerebrospinal fluid. The outcomes were evaluated during pre- (2013–2017) and post-intervention periods (2018–2022). Interrupted time-series analysis was used, and comparison of AUR calculated per each 3-month time block and the slope changes were conducted across the pre- and post-intervention periods regarding total patients and subgroups.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;A total of 41,253 infants were included, with 22,644 (55%) being male. The AUR was significantly lower among infants from the post- vs. those from the pre-intervention periods (152 vs. 184, p &lt; 0.0001). Among 35,670 infants without culture-proven sepsis or necrotizing enterocolitis ≥ Stage 2, AUR was significantly lower in the post-intervention group vs. the pre-intervention group (110 vs. 136, p &lt; 0.0001). Interrupted time-series showed significant reduction in AUR during both pre- and post-intervention periods among all infants with and without culture proven sepsis or necrotizing enterocolitis ≥ Stage 2 (all p &lt; 0.0001), as well as those born at &lt;29 weeks gestational age.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;A comprehensive, network-wide quality improvement initiatives led to a significant and sustained reduction in antimicrobial use among preterm infants born at &lt;33 weeks gestational age with and without culture-proven sepsis or necrotizing enterocolitis ≥ Stage 2.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;This study was supported by the &lt;span&gt;Canadian Institutes of Health Research&lt;/span&gt; Project Grant 2019 (201903PJT-420294-CA2-CAAA-245530), matched funding from the &lt;span&gt;British Columbia Women's Health Foundation&lt;/span&gt; and start-up funding from the Women and Children's Health Research Institute, &lt;span&gt;University of Alberta&lt;/span&gt;. The coordinating center in Toronto is funded by the &lt;span&gt;Canadian Institutes of Health Research&lt;/span&gt; grant for the Canadian Preterm Birth Net","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100942"},"PeriodicalIF":7.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study","authors":"Emanuel Krebs ,&nbsp;Deirdre Weymann ,&nbsp;Cheryl Ho ,&nbsp;Ian Bosdet ,&nbsp;Janessa Laskin ,&nbsp;Howard J. Lim ,&nbsp;Stephen Yip ,&nbsp;Aly Karsan ,&nbsp;Timothy P. Hanna ,&nbsp;Samantha Pollard ,&nbsp;Dean A. Regier","doi":"10.1016/j.lana.2024.100936","DOIUrl":"10.1016/j.lana.2024.100936","url":null,"abstract":"<div><h3>Background</h3><div>Multi-gene panel sequencing streamlines treatment selection for advanced non-small cell lung cancer (NSCLC). Implementation continues to be uneven across jurisdictions, partly due to uncertain clinical and economic impacts. In British Columbia (BC), Canada, the public healthcare system reimbursed a multi-gene panel in September 2016. This study determined the population-level cost-effectiveness of publicly reimbursed multi-gene panel sequencing compared to single-gene testing for advanced NSCLC.</div></div><div><h3>Methods</h3><div>Our population-based retrospective study design used patient-level linked administrative health databases. We considered adult BC residents with a panel-eligible lung cancer diagnosis between September 2016 and December 2018. Using a machine learning approach, we conducted 1:1 genetic algorithm matching of recipients receiving multi-gene panel sequencing to controls receiving single-gene testing, maximising balance on observed demographic and clinical characteristics. Following matching, we estimated mean three-year survival time and costs (public healthcare payer perspective; 2021 CAD) and calculated the incremental net monetary benefit (INMB) for life-years gained (LYG) at conventional willingness-to-pay thresholds using inverse probability of censoring weighted linear regression and nonparametric bootstrapping.</div></div><div><h3>Findings</h3><div>We matched 858 panel-eligible advanced NSCLC patients to controls, achieving balance for the 16 included covariates. Average test turnaround times were 18.6 days for multi-gene panel sequencing and 7.0 days for single-gene testing. After matching, mean incremental costs were $3529 (95% CI: −$4268, $10,942) and mean incremental LYG were 0.08 (95% CI: −0.04, 0.18). Among the 1000 bootstrap samples, 14.5% had lower costs and increased survival and 78.6% had higher costs and increased survival. The INMB was $523 (95% CI: −$6256, $7023) at $50,000/LYG, with a 57.5% probability of being cost-effective, and $4575 (95% CI: −$5468, $14,064) at $100,000/LYG, with an 84.0% probability of being cost-effective.</div></div><div><h3>Interpretation</h3><div>Using population-based real-world data, we found a moderate to high probability that panel-based testing to inform targeted treatment for NSCLC would be cost-effective at higher thresholds.</div></div><div><h3>Funding</h3><div>This research was supported by <span>Genome British Columbia</span>/<span>Genome Canada</span> (G05CHS) and the <span>Terry Fox Research Institute</span>.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100936"},"PeriodicalIF":7.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased risks of mosquito-borne disease emergence in temperate regions of South America","authors":"Elizabet L. Estallo ,&nbsp;María Soledad López ,&nbsp;Francisco Ludueña-Almeida ,&nbsp;Magali I. Madelón ,&nbsp;Federico Layún ,&nbsp;Michael A. Robert","doi":"10.1016/j.lana.2024.100946","DOIUrl":"10.1016/j.lana.2024.100946","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"40 ","pages":"Article 100946"},"PeriodicalIF":7.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Candidate drug repurposing for malaria: perspectives for optimising clinical trials","authors":"J. Luis Espinoza","doi":"10.1016/j.lana.2024.100939","DOIUrl":"10.1016/j.lana.2024.100939","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"41 ","pages":"Article 100939"},"PeriodicalIF":7.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}